Avistone

Avistone, headquartered in Beijing, China, has been dedicated to the development of precision oncology therapies for nearly a decade, with a broad oncology pipeline focused on the treatment of lung cancer. The company’s most advanced pipeline candidate is a c-Met inhibitor currently in late-stage clinical development, targeting non-small cell lung cancer and glioblastoma patients with specific genetic profiles. This product has been granted Breakthrough Therapy designation by the NMPA. Avistone boasts an extensive pipeline of targeted therapies addressing molecular drivers of cancer, including two clinical-stage candidates and several programs in ongoing preclinical development. The company also has multiple therapeutic compound candidates in preclinical and IND-enabling studies.